Application of the superselective roentgen-endovascular chemoembolization in the treatment of patients with localised prostate cancer: our first experience

Neymark A.I., Tachalov M.A., Neymark B.A., Arzamascev D.D., Torbik D.V.

Aim of the study: to evaluate efficacy and safety of the superselective roentgen – endovascular chemoembolization (SREC) in patients with localized prostate cancer (PCa).

Materials and methods. SREC was carried out in PCa patients with a mean age of 72.3±2.1 years in a period from 2011 to 2014. Mean total PSA level was 13.1±3.9 ng/ml (range 0.8-17 ng/ml). Mean prostate volume was 59±9.3 ml (41-93 ml). Lower urinary tracts symptoms were evident in 66.6% of patients. Follow up was in the range from 3 up to 24 months.

Results. Effect aрЮer SREC was evident in 30 patients (83.3%), objectively . PSA response, decrease in prostate volume and increase in micturition quality. Mean total PSA at follow up point 6 months was 3.4Ѓ}0.02 ng/ml. By last follow up it PSA level was decreased by 60% with regard to the initial value (p<0.05).

Significant reduction in prostate volume was evident at 3 months after SREC (p< 0.05) and was at an average 49.1% from the initial value (29.6±4.8 ml). All patients with obstructive voiding reported amelioration. Maximal effect on Qmax and IPSS score was observed at 6 months after SREC.

Control biopsy was carried out 12 months aрЮer SREC in 16 patients. In 12 cases fibrosis and epithelial dystrophy were the findings in the absence of cell atypia, in 2 patients . treatment-induced pathomorphosis.

SREC had a very good safety profile without any substantial complications.

Conclusion. Our first experience with chemoembolization in patients with PCa showed efficacy and safety of this method in patients not fit for radical treatment.

 

AttachmentSize
Скачать статью989.98 KB